Court orders KRW 10 billion share seizure, testing Hanmi Science stock

Published on 10/20/2026 at 04:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit KRW 367.9 billion, up 8.7 percent in the second quarter. Hanmi Science stock faces October 27 results after KRW 59.1 billion operating profit.

Ownership pressure and operating scale

A court ordered a KRW 10.0 billion provisional share seizure on October 13, 2026.
Second-quarter revenue reached KRW 367.9 billion, up 8.7 percent year over year.
The next earnings release is scheduled for October 27, 2026.

Hanmi Science, KR7008930000, Illustration mit AI erstellt.

Hanmi Science (ISIN KR7008930000) faces a fresh control test after a court ordered a provisional seizure of KRW 10.0 billion of shares linked to shareholder Shin Dong-kuk. ChosunBiz reported the development on October 13, 2026, adding to the governance pressure around the holding company.

Three events reshape the story

On October 2, 2026, Shin Dong-kuk disclosed a planned purchase of 1,382,832 Hanmi Science shares for KRW 69.3 billion, according to ChosunBiz. On October 7, 2026, Hanmi Pharmaceutical received approval for the EPPE obesity treatment, a milestone that helped drive a 13.94 percent after-hours gain in Hanmi Science, Seoul Economic Daily reported. On October 13, 2026, the court ordered the KRW 10.0 billion provisional seizure, according to ChosunBiz.

What does the business contribute?

The operating picture gives the ownership dispute a measurable counterweight. Hanmi Science reported second-quarter 2026 revenue of KRW 367.9 billion, up 8.7 percent from a year earlier, while operating profit reached KRW 59.1 billion, or a 16.1 percent margin, according to ATS View. The company operates as a holding group with pharmaceutical wholesale, healthcare, holding and other businesses, according to MarketScreener.

Which dates matter next?

The next scheduled earnings release is October 27, 2026, for the third quarter, according to MarketScreener. A second dated event is November 16, 2026, the filing deadline for the quarterly report listed by ATS View. For investors, the next report will show whether operating earnings can keep pace with the group-level governance dispute.

Stock price and valuation context

Hanmi Science was last quoted at KRW 44,700.00 on the Korea Exchange on October 20, 2026 at 11:26 a.m. KST. Its market capitalization was KRW 3.0 trillion at the same market-data snapshot, while the Korea Exchange listing is identified as 008930 in company market information.